Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings

References

• RydénLGrantPJAnkerSDESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEur Heart J201334393035308723996285
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJGLichtensteinAHAmerican College of Cardiology/American Heart Association Task Force on Practice GuidelinesACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20146325 Pt B2889293424239923
   PubMed Web of Science ®Google Scholar
• AndersonTJGrégoireJPearsonGJ2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adultCan J Cardiol201632111263128227712954
   PubMed Web of Science ®Google Scholar
• CatapanoALGrahamIDe BackerGESC Scientific Document Group2016ESC/EAS guidelines for the management of dyslipidaemiasEur Heart J201637392999305827567407
   PubMed Web of Science ®Google Scholar
• Ministry of Health MalaysiaClinical Practice GuidelinesManagement of Dyslipidaemia 20175th ednPutrajayaMinistry of Health Malaysia2017
   Google Scholar
• Ministry of Health MalaysiaMalaysian Clinical Practice GuidelinesManagement of Type 2 Diabetes Mellitus5th ednPutrajayaMinistry of Health Malaysia20151129
   Google Scholar
• BellDSAl BadarinFO’KeefeJHJrTherapies for diabetic dyslipidaemiaDiabetes Obes Metab201113431332521205114
   PubMed Web of Science ®Google Scholar
• FungCSCWanEYFChanAKCLamCLKStatin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort studyBMC Cardiovasc Disord201717116628645252
   PubMed Web of Science ®Google Scholar
• ChenPHWangJSLinSYEffects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetesCurr Med Res Opin201834111885189229429368
   PubMed Web of Science ®Google Scholar
• ReinerŽDe BacquerDKotsevaKEUROASPIRE III Study GroupTreatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III surveyAtherosclerosis2013231230030724267243
   PubMed Web of Science ®Google Scholar
• FinnikinSRyanRMarshallTStatin initiations and QRISK2 scoring in UK general practice: a THIN database studyBr J Gen Pract201767665e881e88729061715
   PubMed Web of Science ®Google Scholar
• NavarAMWangTYLiSLipid management in contemporary community practice: results from the Provider Assessment of Lipid Management (PALM) RegistryAm Heart J2017193849229129260
   PubMed Web of Science ®Google Scholar
• YehYTYinWHTsengWKTaiwanese Secondary Prevention for Patients with AtheRosCLErotic Disease (T-SPARCLE) Registry InvestigatorsLipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? – Data from a multicenter registry cohort study in TaiwanPLoS One20171210e018686129073192
   PubMed Web of Science ®Google Scholar
• BennieMGodmanBBishopICampbellSMultiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in ScotlandExpert Rev Pharmacoecon Outcomes Res201212112513022280202
   PubMed Web of Science ®Google Scholar
• HongKNFusterVRosensonRSRosendorffCBhattDLHow low to go with glucose, cholesterol, and blood pressure in primary prevention of CVDJ Am Coll Cardiol201770172171218529050566
   PubMed Web of Science ®Google Scholar
• ElnaemMHMohamedMHNHuriHZAzarismanSMElkalmiRMStatin therapy prescribing for patients with type 2 diabetes mellitus: a review of current evidence and challengesJ Pharm Bioallied Sci201792808728717329
   PubMedGoogle Scholar
• Siti FauziahAKamarudinANnanOMalaysian Statistics on Medicines 2009 & 2010MalaysiaPharmaceutical Services Division and Clinical Research Centre, Ministry of Health2014
   Google Scholar
• ElnaemMMHNik MohamedMMHHuriHZAzarismanSMPatterns of statin therapy prescribing among hospitalized patients with Type 2 diabetes mellitus in two Malaysian tertiary hospitalsTrop J Pharm Res2017161230053011
   Web of Science ®Google Scholar
• ChewBHIsmailMLeePYDeterminants of uncontrolled dyslipidaemia among adult type 2 diabetes in Malaysia: the Malaysian Diabetes Registry 2009Diabetes Res Clin Pract201296333934722305940
   PubMed Web of Science ®Google Scholar
• CzarkowskiMHelsinki Declaration-next versionPol Merkur Lekarski201436215295297 Polish24964503
   PubMedGoogle Scholar
• GantCMBinnenmarsSHHarmelinkMReal-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factorsNutr Diabetes2018812429695715
   PubMed Web of Science ®Google Scholar
• LeeBDumrongkitchaipornKStatin intensity regimens in Thai Type 2 diabetic patients who achieved LDL-C targetsJ Med Assoc Thai20171005603611
   Google Scholar
• KotsevaKDe BacquerDDe BackerGOn Behalf Of The Euroaspire InvestigatorsLifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regionsEur J Prev Cardiol201623182007201827638542
   PubMed Web of Science ®Google Scholar
• JozwiakJChruscielPTomaszewskiMLipids profile and efficacy of treatment of dyslipidemia in primary care in Poland. Results of lipidogram 5 years study (2004–2010)Atherosclerosis2017263e187
   Web of Science ®Google Scholar
• JonesNRFischbacherCMGuthrieBScottish Diabetes Research Network Epidemiology GroupFactors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006–2008Diabet Med201431664064624533646
   PubMed Web of Science ®Google Scholar
• KuiperJGSanchezRJHoubenEUse of lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in the NetherlandsClin Ther2017394819827.e128347514
   PubMed Web of Science ®Google Scholar
• KrummeAAFranklinJMIsamanDLPredicting 1-year statin adherence among prevalent users: a retrospective cohort studyJ Manag Care Spec Pharm201723449450228345442
   PubMed Web of Science ®Google Scholar
• De BackerGDe BacquerDRydénLEUROASPIRE investigatorsLifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveysEur J Prev Cardiol201623151618162727084894
   PubMed Web of Science ®Google Scholar
• GybergVDe BacquerDDe BackerGEUROASPIRE InvestigatorsPatients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the Euro Observational Research Programme of the European Society of CardiologyCardiovas Diabetol2015141111
   PubMed Web of Science ®Google Scholar
• LamaSSourayaDYoussefFStatin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patientsInt J Clin Pharm201739491992628523462
   PubMed Web of Science ®Google Scholar
• GuglielmiVBelliaAPecchioliSEffectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary careAtherosclerosis2017263364128599257
   PubMed Web of Science ®Google Scholar
• AguiarCAlegriaEBonadonnaRCA review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate-statin combination therapyAtheroscler Suppl20151911226315511
   PubMed Web of Science ®Google Scholar
• FerrariRAguiarCAlegriaECurrent practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaEur Heart J Suppl201618Suppl CC2C1228533705
   PubMed Web of Science ®Google Scholar
• RussellCShethSJacobyDA clinical guide to combination lipid-lowering therapyCurr Atheroscler Rep20182041929516190
   PubMed Web of Science ®Google Scholar
• KarmaliKNLeeJYBrownTPersellSDPredictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centersPrev Med20168817618127090436
   PubMed Web of Science ®Google Scholar
• SchoenMWTabakRGSalasJScherrerJFBuckholdFRComparison of adherence to guideline-based cholesterol treatment goals in men versus womenAm J Cardiol20161171485326589821
   PubMed Web of Science ®Google Scholar
• DimmittSBStampferHGWarrenJBThe pharmacodynamic and clinical trial evidence for statin doseBr J Clin Pharmacol20188461128113529393975
   PubMed Web of Science ®Google Scholar
• RamliAAljunidSMSulongSMd YusofFANational Drug Formulary review of statin therapeutic group using the multiattribute scoring toolTher Clin Risk Manag2013949150424353428
   PubMed Web of Science ®Google Scholar
• GuQPaulose-RamRBurtVKitBPrescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012NCHS Data Brief201417718
   Google Scholar
• ThaiMReeveEHilmerSNQiKPearsonSAGnjidicDPrevalence of statin-drug interactions in older people: a systematic reviewEur J Clin Pharmacol201672551352126790666
   PubMed Web of Science ®Google Scholar
• MaghsoodiNWierzbickiASStatins: general safety profile and association with myopathyClin Pharm201685125
   Google Scholar
• MorivalCWesterlynckRBouzilléGCuggiaMLe CorrePPrevalence and nature of statin drug-drug interactions in a university hospital by electronic health record miningEur J Clin Pharmacol201874452553429255993
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes-2016Am Diabetes Assoc201639Suppl 1S1S112
   Google Scholar
• GrundySMPrimary prevention of cardiovascular disease with statins: assessing the evidence base behind clinical guidanceClin Pharm201682
   Google Scholar